Anders Månsson
Chief Executive Officer at Anders Månsson Business Development AB
Net worth: 39 560 $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leif Gunnar Håkansson | M | 82 |
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Tina Bjørnlund Bønsdorff | M | 53 |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 14 years |
| Jan Peter Ernst Christensson | M | - |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Bo Anders Ljungqvist | M | 74 |
RhoVac ApS
 RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The private company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | 16 years |
| Tomas D. Bertmark | M | - |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Ingrid Linda Marie Neckmar | F | 51 | 4 years | |
| Marc Richard Tullgren | M | 59 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Jerker Olof Ringström | M | 81 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Ingrid Atteryd Heiman | F | 66 | 3 years | |
| Thora Johanna Jonasdottir | M | 59 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 14 years |
| Per Svangren | M | 51 | 3 years | |
| Christopher Bravery | M | 57 | 3 years | |
| Sven Fredrik Tiberg | M | 61 | 3 years | |
| Peter Buhl Jensen | M | 69 | 3 years | |
| Stig Thomas Jivung | M | 73 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Kia Bengtsson | F | - | 2 years | |
| Anna Jönsson | F | 40 | 3 years | |
| Jan van de Winkel | M | 63 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 7 years |
| Jan Nilsson | M | 75 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Christopher Tovey | M | 59 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Adrian Senderowicz | M | 60 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 2 years |
| Tommy Evert Andersson | M | 68 |
University of Lund
| 28 years |
| Carl Johan Kördel | M | 62 |
University of Lund
| 30 years |
| Derek Gregory Batcheller | M | 67 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Leiv Askvig | M | 67 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | - |
| Mikael Ørum | M | 71 |
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The private company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | 10 years |
| Lars Olof Hedbys | M | 67 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Margareta Linden | M | - |
University of Lund
| 31 years |
| Jan Talts | M | 59 | 7 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marten Steen | M | 49 |
University of Lund
| 9 years |
| Filip Tobias Petersson | M | 47 |
University of Lund
| 10 years |
| John Carsten Mehlbye | M | - |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | - |
| Bengt Karlsson | M | - |
University of Lund
| 5 years |
| Måns Nicklas Lidgren | M | 47 |
University of Lund
| 5 years |
| Inga Sarah Maria Fredriksson | M | 56 |
University of Lund
| 5 years |
| Lars Stigsson | M | 71 | 2 years | |
| Fredrik Häglund | M | 49 |
University of Lund
| 6 years |
| Susanna Schneeberger | F | 51 |
University of Lund
| 1 years |
| Roy Hartvig Larsen | M | 62 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 14 years |
| Johny Humaloja | M | 58 | 2 years | |
| Rikard Krook | M | 57 |
University of Lund
| 5 years |
| Max Håkan Mitteregger | M | 61 | 1 years | |
| Cecilia Ganslandt | M | - |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 1 years |
| Lars Thomas Lidgren | M | 53 |
University of Lund
| 4 years |
| Sven Anders Mikael Akke | M | 63 |
University of Lund
| 3 years |
| Maria Larsen | F | - |
University of Lund
| 4 years |
| Kristín Haraldsdóttir | F | 54 |
University of Lund
| 3 years |
| Thomas Hartwig | M | - |
University of Lund
| 3 years |
| Johan Moeschlin | M | - |
University of Lund
| 4 years |
| Johan Drott | M | 58 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | - |
| Christina Östberg Lloyd | M | 63 |
University of Lund
| 3 years |
| Lars Bertil Christer Wingren | M | 58 |
University of Lund
| 3 years |
| Anna Maria Inga Söderblom | M | 61 |
University of Lund
| 4 years |
| Peter Platan | M | - |
University of Lund
| 5 years |
| Carl Magnus Högerkorp | M | 54 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | 2 years |
| Nicklas Lindberg | M | - |
University of Lund
| 4 years |
| Johan Henrik Jardevall | M | 50 |
University of Lund
| 3 years |
| Louise Wendel | F | 49 |
University of Lund
| 6 years |
| Christian Merheim | M | 52 |
University of Lund
| 1 years |
| Mikael Lundgren | M | 52 |
University of Lund
| 3 years |
| Peter Montgomery | M | 50 |
University of Lund
| 5 years |
| Jonas Måhlén | M | 56 |
University of Lund
| 6 years |
| Susan Gustafsson | F | 51 |
University of Lund
| 4 years |
| Peter Heerma | M | 53 |
University of Lund
| 1 years |
| Louise Öfverström | F | 49 |
University of Lund
| 2 years |
| Mattias Larsson | M | - |
University of Lund
| 4 years |
| Cecilia Schéele | F | - |
University of Lund
| 4 years |
| Johan Ek | M | - |
University of Lund
| 5 years |
| Kjoller Kim | M | - |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | - |
| Martin Anders Persson | M | 49 |
University of Lund
| 4 years |
| Robert Puskaric | M | 55 |
University of Lund
| 4 years |
| Anna Karolina Olofsson | F | - |
University of Lund
| 1 years |
| Mikael Kretz | M | 49 |
University of Lund
| 3 years |
| Christian Kjellman | M | 57 |
University of Lund
| 3 years |
| Jan Staffan Helgesson | M | 56 |
University of Lund
| 4 years |
| Dag Jörgen Urban Gustafsson | M | - |
University of Lund
| 3 years |
| Eran Gilad | M | - |
University of Lund
| 1 years |
| Tobias Järnblad | M | - |
University of Lund
| 4 years |
| Lars-Erik Magnus Wernersson | M | 56 |
University of Lund
| 3 years |
| Karin Marie Widstrand | M | 60 |
University of Lund
| 3 years |
| Ola Karlsson | M | - |
University of Lund
| 3 years |
| Lars Thomas Laurell | M | 63 |
University of Lund
| 3 years |
| Dario Kriz | M | 58 |
University of Lund
| 3 years |
| Karl Stefan Olofsson | M | 56 |
University of Lund
| 4 years |
| Margareta Ingegerd Krook | M | 57 |
University of Lund
| 3 years |
| Åsa Schiött | M | - |
University of Lund
| 3 years |
| Per Martin Made | M | 55 |
University of Lund
| 4 years |
| Svend Andersen | M | 62 |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | 1 years |
| Karl Birger Hillgård | M | 57 |
University of Lund
| 2 years |
| Helene Dérand | M | - |
University of Lund
| 3 years |
| Maija Dobele | F | 47 |
University of Lund
| 1 years |
| David Rikard Martinsson Holmdahl | M | 71 |
University of Lund
| 14 years |
| Anna Ronnelin | F | 56 |
University of Lund
| 4 years |
| Staffan Skogvall | M | 61 |
University of Lund
| 3 years |
| Marcus Eriksson | M | 50 |
University of Lund
| 4 years |
| Patrik Romberg | M | 58 |
University of Lund
| 3 years |
| Lars A. Sjöbring | M | 56 |
University of Lund
| 3 years |
| Per Johan Anell | M | 56 |
University of Lund
| 4 years |
| Dan Wahrenberg | M | 55 |
University of Lund
| 2 years |
| Ann-Sofie Davidsson | F | 52 |
University of Lund
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 88 | 88.00% |
| Denmark | 7 | 7.00% |
| Norway | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Anders Månsson
- Personal Network
